Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-31
2011-05-31
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000, C530S397000
Reexamination Certificate
active
07951771
ABSTRACT:
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
REFERENCES:
patent: 4973577 (1990-11-01), Vale, Jr. et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5847078 (1998-12-01), Eto et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 6093547 (2000-07-01), Jin et al.
patent: 6132988 (2000-10-01), Sugino et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6440930 (2002-08-01), Rinella, Jr.
patent: 6451334 (2002-09-01), Perrine
patent: 6599876 (2003-07-01), Kojima
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7202210 (2007-04-01), Wolfman et al.
patent: 7560441 (2009-07-01), Wolfman et al.
patent: 7612041 (2009-11-01), Knopf et al.
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2004/0197828 (2004-10-01), Gaddy
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0068468 (2006-03-01), Knopf et al.
patent: 2006/0210657 (2006-09-01), Chou
patent: 2007/0048830 (2007-03-01), Gilbert et al.
patent: 2007/0149455 (2007-06-01), Wolfman et al.
patent: 2007/0172956 (2007-07-01), Magari et al.
patent: 2007/0184052 (2007-08-01), Lin et al.
patent: 2007/0249022 (2007-10-01), Knopf et al.
patent: 2007/0275895 (2007-11-01), Duan et al.
patent: 2007/0292885 (2007-12-01), Bejanin et al.
patent: 2008/0021104 (2008-01-01), Tarallo
patent: 2008/0075692 (2008-03-01), Perrine
patent: 2008/0089897 (2008-04-01), Wolfman
patent: 2008/0139590 (2008-06-01), Qian et al.
patent: 2009/0005308 (2009-01-01), Knopf et al.
patent: 2009/0047281 (2009-02-01), Sherman
patent: 2009/0074768 (2009-03-01), Knopf et al.
patent: 2009/0087433 (2009-04-01), Wolfman et al.
patent: 2009/0098113 (2009-04-01), Knopf et al.
patent: 2009/0099086 (2009-04-01), Knopf et al.
patent: 2009/0118188 (2009-05-01), Knopf et al.
patent: 2009/0142333 (2009-06-01), Knopf et al.
patent: 2009/0163417 (2009-06-01), Sherman
patent: 1174149 (2002-01-01), None
patent: WO-92/20793 (1992-11-01), None
patent: WO-95/10611 (1995-04-01), None
patent: WO-99/06559 (1999-02-01), None
patent: WO-00/43781 (2000-07-01), None
patent: WO-02/10214 (2002-02-01), None
patent: WO-02/43759 (2002-06-01), None
patent: WO-02/085306 (2002-10-01), None
patent: WO-03/006057 (2003-01-01), None
patent: WO-03/072808 (2003-09-01), None
patent: WO-2004/039948 (2004-05-01), None
patent: WO-2004/108157 (2004-12-01), None
patent: WO-2005/009460 (2005-02-01), None
patent: WO-2005/028517 (2005-03-01), None
patent: WO-2005/094871 (2005-10-01), None
patent: WO-2005/097825 (2005-10-01), None
patent: WO-2006/002387 (2006-01-01), None
patent: WO-2006/012627 (2006-02-01), None
patent: WO-2006/039400 (2006-04-01), None
patent: WO-2006/068468 (2006-06-01), None
patent: WO-2006/083183 (2006-08-01), None
patent: WO-2006/088972 (2006-08-01), None
patent: WO-2007/053775 (2007-05-01), None
patent: WO-2007/062188 (2007-05-01), None
patent: WO-2007/067616 (2007-06-01), None
patent: WO-2008/031061 (2008-03-01), None
patent: WO-2008/060139 (2008-05-01), None
patent: WO-2008/076437 (2008-06-01), None
patent: WO-2008/097541 (2008-08-01), None
patent: WO-2008/100384 (2008-08-01), None
patent: WO-2008/109167 (2008-09-01), None
Wells, Biochemistry 29:8509-8517, 1990.
Elisabetta del Re et al., “Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System,” The Journal of Biological Chemistry, 279(51):53126-53135 (2004).
Donaldson et al., “Molecular Cloning and Binding Properties of the Human Type II Activin Receptor,” Biochemical and Biophysical Research Corporation, 184(1):310-316 (1992).
Gray et al., “Identification of a Binding Site on the Type II Activin Receptor for Activin and Inhibin,” The Journal of Biological Chemistry, 275(5):3206-3212 (2000).
Thompson et al., “Structures of an ActRIIB:Activin A Complex Reveal a Novel Binding Mode for TGF-beta Ligand:Receptor Interactions,” EMBO J. 22(7):1555-1566 (2003).
Mickle, Ph.D., John, et al, “Genotype-Phenotype Relationships in Cystic Fibrosis,” Medical Clinics of North America, vol. 84, No. 3, pp. 597-607, 2000.
Lee et al., “Regulation of Muscle Growth by Multiple Ligands Signaling Through Activin Type II Receptors,” PNAS 102(50):18117-18122 (2005).
Centrella et al., “Activin-A Binding and Biochemical Effects in Osteoblast-Enriched Cultures from Fetal-Rat Parietal Bone,” Molecular and Cellular Biology, 11(1):250-58 (1991).
Hashimoto et al., “Functional Regulation of Osteoblastic Cells by the Interaction of Activin-A with Follistatin,” The Journal of Biological Chemistry 267(7):4999-5004 (1992).
Oue et al., “Effect of Local Injection of Activin A on Bone Formation in Newborn Rats,” Bone 15(3):361-366 (1994).
Shuto et al., “Osteoblasts Express Types I and II Activin Receptors During Early Intramembranous and Endochondral Bone Formation,” Journal of Bone Mineral Research 12(3):403-411 (1997).
Ogawa et al., “Bovine Bone Activin Enhances Bone Morphogenetic Protein-Induced Ectopic Bone Formation,” The Journal of Biological Chemistry 267(20):14233-14237 (1992).
Nagamine et al., “Immunohistochemical Detection of Activin A, Follistatin, and Activin Receptors during Fracture Healing in the Rat,” Journal of Orthopaedic Research 16:314-321 (1998).
Ikenoue et al., “Inhibitory Effects of Activin-A on Osteoblast Differentiatin During Cultures of Fetal Rat Calvarial Cells,” Journal of Cellular Biochemistry 75:206-214 (1999).
Fuller et al., “Activin A Is an Essential Cofactor for Osteoclast Induction,” Biochemical and Biophysical Research Communications 268:2-7 (2000).
Sakai et al., “Activin Increases Bone Mass and Mechanical Strength of Lumbar Vertebrae in Aged Ovariectomized Rats,” Bone 27(1):91-96 (2000).
Sakai, et al., “Osteogenic Activity of Activin in Young Normal Rats and Young Adult and Aged Rats after Ovarlectomy,” Bone 23:(Suppl.) 467 (1998).
Sakai et al., “Local Administration of Activin Promotes Fracture Healing in the Rat Fibula Fracture Model,” Bone 25(2):191-196 (1999).
Sakai et al., “Activin Release From Bone Coupled to Bone Resorption in Organ Culture of Neonatal Mouse Calvaria,” Bone 26(3):235-240 (2000).
Murase et al., “Possible Involvement of Protein Kinases and Smad2 Signaling Pathways on Osteoclast Differentiation Enhanced by Activin A,” Journal of Cellular Physiology 188:236-242 (2001).
Sakai et al., “Involvement of Activin in the Regulation of Bone Metabolism,” Molecular and Cellular Endocrinology 180:183-188 (2001).
Sakai et al., “Activin Enhances Osteoclast-Like Cell Formation in Vitro,” Biochemical and Biophysical Research Communications, 195(1):39-46 (1993).
Funaba et al., “Expression and Localization of Activin Receptors During Endochondral Bone Development,” European Journal of Endocrinology, 144:63-71 (2001).
Gaddy-Kurten et al., “Inhibin Suppresses and Activin Stimulates Osteoblastogenesis and Osteoclastogenesis in Murine Bone Marrow Cultures,” Endocrinology 143(1):74-83 (2002).
Wiater, et al., “Inhibin is an Antagonist of Bone Morphogenetic Protein Signaling,” The Journal of Biological Chemistry 278(10):7934-7941 (2003).
Sun et al., “FSH Directly Regulates Bone Mass,” Cell 125:247-260 (2006).
Meriggiola et al., “Follistatin Decreases Activin-Stimulated FSH Secretion with No Effect on GnRH-Stimulated FSH Secretion in Prepubertal Male Monkeys,” Endocrinology 134(4):1967-1970 (1994).
Knight, “Roles of Inhibins, Activins, and Follistatin in the Female Reproductive System,” Frontiers in Neuroendocrinology 17:476-509 (1996).
Daluiski et al., “Bone Morphogenetic Protein-3 is a Negative Regulator of Bone Density,” Nature Genetics 2
Knopf John
Seehra Jasbir
Acceleron Pharma Inc.
Chandra Gyan
Landsman Robert
Ropes & Gray LLP
LandOfFree
Activin-ActRIIa antagonists and uses for promoting bone growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activin-ActRIIa antagonists and uses for promoting bone growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activin-ActRIIa antagonists and uses for promoting bone growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2677811